Perhexiline - Heart Metabolics

Drug Profile

Perhexiline - Heart Metabolics

Alternative Names: Perhexiline maleate; WSM 3978 G

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HMBL Limited
  • Developer Heart Metabolics Limited
  • Class Antihypertensives; Cyclohexanes; Ischaemic heart disorder therapies; Piperidines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Carnitine O-palmitoyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypertrophic cardiomyopathy

Most Recent Events

  • 26 Aug 2017 Efficacy and pharmacodynamics data from a phase I trial in healthy volunteers presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2017)
  • 02 Aug 2017 Heart Metabolics Limited terminates a phase II trial due to lack of efficacy in Hypertrophic cardiomyopathy in USA (PO) (NCT02862600)
  • 12 Jul 2017 Heart Metabolics withdraws a phase III trial prior to enrolment for Hypertrophic cardiomyopathy in USA due to lack of efficacy in a preceding study (PO) (NCT02431221)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top